You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
By extending Terra to the Microsoft Azure cloud, the Broad and Verily Life Sciences hope to facilitate better data sharing, analysis, and reuse.
A new partnership between Microsoft, the Broad, and Verily Life Sciences aims to improve collaboration among Terra users worldwide.
The methods, both published in Nature Biotechnology this week, result in completely phased haplotypes, without the need for sequencing parental samples.
The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.
Kaiser Health News reports San Francisco and Alameda counties in California are no longer using Verily Life Sciences' COVID-19 testing program, but a Verily spokesperson says it currently working with multiple Bay Area counties.
In a PrecisionFDA challenge, DeepVariant calls of PacBio HiFi reads topped 99 percent precision and recall for SNVs and indels, bringing HiFi in line with Illumina.
Verily's test is a modified version of Thermo Fisher Scientific's authorized TaqPath COVID-19 Combo Kit that can be used with pooled samples.
The public-private partnership has published a paper on a list of indels larger than 50 bp that is already being used to develop new methods.
Verily is adapting its Project Baseline to study the immune system response to SARS-CoV-2, CNBC reports.
Cerevance, a drug discovery firm employing the transcriptome sequencing method, raised $45 million in Series B financing earlier this month.
The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.
According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.